• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

    129.46 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Blueprint Medicines Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 Next >
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
     
    Via Benzinga
    Decoding 6 Analyst Evaluations For Blueprint Medicines
     
    Via Benzinga
    (BPMC) - Analyzing Blueprint Medicines's Short Interest
     
    Via Benzinga
    Blueprint Medicines Corp. (NASDAQ: BPMC) Climbs to New 52-Week High
    Via Investor Brand Network
    Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
    U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
    The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report. 
    Via Investor's Business Daily
    Blueprint Medicines's Earnings Outlook
     
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
     
    Via Benzinga
    Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
     
    Via Benzinga
    Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
     
    Via Benzinga
    Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?
    Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. 
    Via Talk Markets
    Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
    Via Benzinga
    The Latest Analyst Ratings for Blueprint Medicines
     
    Via Benzinga
    Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
     
    Via Benzinga
    Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
     
    Via Benzinga
    Why Blueprint Medicines Stock Soared Today
    The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit. 
    Via The Motley Fool
    12 Health Care Stocks Moving In Thursday's Intraday Session
     
    Via Benzinga
    Blueprint Medicines Corp. (NASDAQ: BPMC) Leading the Way in Thursday Trading Based on Percentage Gain
    Via Investor Brand Network
    Blueprint Medicines's Earnings: A Preview
     
    Via Benzinga
    Analyst Ratings for Blueprint Medicines
     
    Via Benzinga
    What 15 Analyst Ratings Have To Say About Blueprint Medicines
     
    Via Benzinga
    Why Shares of Blueprint Medicines Are Falling Wednesday
    The company had generally improved earnings. 
    Via The Motley Fool
    Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers 
    Via Benzinga
    Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
    Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ: BPMC) from $65 to $66  
    Via Benzinga
    A Preview Of Blueprint Medicines's Earnings
     
    Via Benzinga
    IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
    U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    3 Biotech Stocks Using AI to Change Healthcare Forever
    These three biotech firms are leveraging artificial intelligence to revolutionize therapeutics and make disease a thing of the past. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.